XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy

BACKGROUND: Recombinant granulocyte colony-stimulating factors (G-CSFs) such as Filgrastim are used to treat chemotherapy-induced neutropenia. We investigated a new G-CSF, XM02, and compared it to Neupogen™ after myelotoxic chemotherapy in breast cancer (BC) patients. METHODS: A total of 348 patient...

Descripción completa

Detalles Bibliográficos
Autores principales: del Giglio, A, Eniu, A, Ganea-Motan, D, Topuzov, E, Lubenau, H
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2628928/
https://www.ncbi.nlm.nih.gov/pubmed/19014494
http://dx.doi.org/10.1186/1471-2407-8-332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2628928/
https://www.ncbi.nlm.nih.gov/pubmed/19014494
http://dx.doi.org/10.1186/1471-2407-8-332

Ejemplares similares